|1.||Lee, Seung Kyun: 1 article (08/2006)|
|2.||Park, Yong-Soo: 1 article (08/2006)|
|3.||Jeon, Eun-Ju: 1 article (08/2006)|
|4.||Yeo, Sang-Won: 1 article (08/2006)|
|5.||Kim, Dong-Hyun: 1 article (08/2006)|
|6.||Chang, Ki-Hong: 1 article (08/2006)|
10/01/1998 - "Pretreatment of the ears with A-85783 resulted in an inhibition of subsequent PAF-induced inflammation. "
10/01/1998 - "These findings demonstrate that epicutaneous A-85783 is an appropriate tool to study the role of the PAF receptor in cutaneous inflammation, and suggest the possible clinical utility of this new class of antiinflammatory agents."
10/01/1998 - "A-85783 treatment also inhibited phorbol myristic acetate-induced cutaneous inflammation, suggesting that the PAF receptor is involved in the etiology of this experimental dermatitis. "
08/01/2006 - "There were no differences in capillary permeability, subepithelial edema, or infiltration of inflammatory cells between the A-85783 and sTNFRI groups. "
08/01/2006 - "The L-NAME group showed no difference in vascular permeability or subepithelial edema in comparison with the A-85783 and sTNFRI groups, but showed more infiltration of inflammatory cells. "
08/01/2006 - "The L-NAME, A-85783, and sTNFRI groups showed significantly reduced capillary permeability, subepithelial edema, and infiltration of inflammatory cells in comparison with the LPS group. "
06/01/1996 - "The in vivo generation of A-85783 from ABT-299 leads to potent inhibition of PAF-induced inflammatory responses (increased vascular permeability, hypotension and edema) and PAF-induced lethality. "
|3.||Otitis Media with Effusion
|4.||Hypotension (Low Blood Pressure)
|1.||Anti-Inflammatory Agents (Anti-Inflammatories)
|2.||NG-Nitroarginine Methyl Ester (L-NAME)